The choice of blood collection tube is a pivotal, yet often underestimated, variable in therapeutic drug monitoring (TDM) assay validation. Tube materials and additives introduce preanalytical interference through physical adsorption of drugs onto gel separators, surfactant-induced displacement of assay capture antibodies, chemical interactions from anticoagulants, and leaching of plasticizers from stoppers. These mechanisms can artificially lower or elevate measured drug concentrations, directly compromising assay accuracy, precision, and the clinical reliability of TDM results.
Core Takeaway: Blood collection tubes are not inert containers. Gel separator tubes can adsorb lipophilic drugs like phenytoin, reducing measured levels, while surfactant additives in serum separator tubes can strip capture antibodies from solid-phase immunoassays, falsely elevating results. A rigorous, tube-type-specific validation is the only way to prevent this invisible preanalytical bias from undermining therapeutic drug monitoring.
The Chemistry of Preanalytical Interference
Interference does not arise randomly. It follows predictable physical and chemical principles rooted in tube composition, additive profiles, and assay design. Understanding these mechanisms is the first step toward effective mitigation.
Adsorption by Gel Separators
Serum separator tubes contain a thixotropic polymer gel that forms a barrier between cells and serum after centrifugation. This gel can adsorb highly lipophilic drugs from the serum phase, particularly when contact time is prolonged or the tube is under-filled.
For example, phenytoin, a classic lipophilic antiepileptic, partitions into the gel matrix over time. The measured serum concentration then drops artificially, potentially leading a clinician to misinterpret a therapeutic level as subtherapeutic. This effect becomes more pronounced as the serum volume decreases relative to the gel surface area.
Surfactant-Induced Surface Desorption
Many gel tubes contain organosilicone surfactants to improve barrier formation and wall coating. These surfactants are not benign. In solid-phase competitive immunoassays, surfactants can displace immobilized capture antibodies from the solid support.
The loss of bound capture antibody reduces the amount of labeled conjugate that can be captured, which in a competitive format generates a signal that mimics an elevated analyte concentration. While this mechanism is well documented for thyroid hormones, it is equally relevant for TDM assays using competitive immunoassay formats, such as those for digoxin or theophylline, where the drug molecule is small and the assay design is inherently susceptible.
Additive Interference: Chelators and Anticoagulants
Tube additives designed to preserve whole blood or accelerate clotting can directly sabotage the subsequent analytical reaction.
EDTA, a chelating agent, sequesters divalent cations like Zn²⁺ and Mg²⁺. These ions are essential cofactors for signal-generating enzymes commonly used in immunoassays, such as alkaline phosphatase. Even microscopic EDTA carryover can inhibit enzyme activity, killing the signal and skewing results. Heparin, meanwhile, can alter the rate of antibody-antigen binding, changing reaction kinetics and producing dose-response curves that deviate from the validated standard.
Leachables from Stoppers and Plastics
The rubber stopper and the plastic wall of the tube are themselves chemical reservoirs. Organic compounds and plasticizers can leach into the sample, especially under temperature extremes or prolonged storage.
These leachables can strip coated antibodies from solid-phase surfaces, inhibit enzyme activity, or displace protein-bound drugs from their carriers. The result is a complex mixture of interferences that can be batch- and supplier-dependent, introducing subtle but systematic errors into TDM measurements.
Understanding the Trade-offs
Convenience and workflow efficiency often push labs toward using a single tube type for multiple assays. That approach invites preanalytical risk. Acknowledging and managing these trade-offs is critical.
The Challenge of Tube Standardization
Standardizing on one collection tube format across all TDM assays simplifies logistics but amplifies interference risk. A tube that is perfect for a binding assay measuring a hydrophilic drug may silently corrupt a competitive assay for a lipophilic compound. Lot-to-lot variability in gel composition or surfactant concentration further erodes confidence, making every new tube shipment a potential source of bias.
The alternative—validating multiple tube types and enforcing strict selection per assay—increases operational complexity and cost. Yet this complexity is the price of diagnostic accuracy. A single falsely elevated tacrolimus level due to surfactant interference can trigger an unnecessary biopsy or an inappropriate dose reduction.
Impact on Different Assay Formats
The susceptibility to tube material interference is not uniform. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) methods may be less prone to the surfactant-antibody desorption effect but remain fully exposed to gel adsorption of lipophilic drugs and ion suppression from leachables. Competitive immunoassays are extraordinarily sensitive to any factor that alters the solid-phase capture surface, making them canaries in the coal mine for surfactant and leachable problems. Diagnostic developers must map their specific assay vulnerability to the known tube interference mechanisms, not assume that one validation fits all.
Making the Right Choice for Your Goal
The path to reliable TDM starts with an intentional tube strategy that matches your primary objective. Use these goal-centric recommendations to focus your efforts.
After defining your core priority, apply the guidance below:
- If your primary focus is assay validation: Test each TDM assay across at least three representative tube types (plain glass, plastic serum separator gel, and a heparin/EDTA plasma tube) using paired patient samples. Quantify bias and establish a tube-specific reference range.
- If your primary focus is optimizing an immunoassay reagent formulation: Screen for surfactant sensitivity by spiking known concentrations of organosilicone compounds into your assay buffer. Adjust the solid-phase coating chemistry or add blocking agents to prevent antibody desorption.
- If your primary focus is setting sample handling protocols for a clinical lab: Specify the exact tube manufacturer and catalog number in your standard operating procedure. Mandate a minimum fill volume and a maximum contact time with the gel before centrifugation, and audit these parameters regularly.
- If your primary focus is troubleshooting an unexplained bias in TDM results: Compare results from the current tube type against a control tube (e.g., additive-free glass) for the same patient population. Look for concentration-dependent differences that mirror gel adsorption or surfactant effects, not just a constant shift.
A blood collection tube is never just a container—it is the first step in your analytical system. Treat it as such, and you will transform preanalytical uncertainty into validated confidence.
Summary Table:
| Interference Mechanism | Source / Tube Component | Analytical & Clinical Impact |
|---|---|---|
| Physical Adsorption | Polymer Gel Separators | Artificially lowers lipophilic drug levels (e.g., Phenytoin). |
| Surface Desorption | Organosilicone Surfactants | Displaces capture antibodies; falsely elevates competitive immunoassay results. |
| Enzyme & Binding Inhibition | Additives (EDTA, Heparin) | Chelates essential cations (inhibits ALP signal) or alters binding kinetics. |
| Leachable Interference | Plasticizers & Stopper Rubber | Causes batch-dependent antibody stripping or ion suppression in LC-MS/MS. |
Eliminate Preanalytical Bias in Your TDM Assays
Don't let invisible tube interferences compromise your diagnostic accuracy. CamelBio provides diagnostic manufacturers, clinical laboratories, and research institutes with one-stop access to high-quality IVD raw materials, technical services, and expert consulting—covering every stage from concept to clinic.
Whether you need robust raw materials resistant to matrix interference or technical guidance on optimizing your immunoassay formulations, our team is here to support you.
👉 Contact CamelBio Today to accelerate your assay validation and deliver reliable, precise TDM solutions.